185 related articles for article (PubMed ID: 3598612)
1. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma.
Buzaid AC; Robertone A; Kisala C; Salmon SE
J Clin Oncol; 1987 Jul; 5(7):1083-9. PubMed ID: 3598612
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
4. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
5. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.
Muss HB; Costanzi JJ; Leavitt R; Williams RD; Kempf RA; Pollard R; Ozer H; Zekan PJ; Grunberg SM; Mitchell MS
J Clin Oncol; 1987 Feb; 5(2):286-91. PubMed ID: 3543247
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients.
Kurzrock R; Rosenblum MG; Quesada JR; Sherwin SA; Itri LM; Gutterman JU
J Clin Oncol; 1986 Nov; 4(11):1677-83. PubMed ID: 3095504
[TBL] [Abstract][Full Text] [Related]
7. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules .
Legha SS; Papadopoulos NE; Plager C; Ring S; Chawla SP; Evans LM; Benjamin RS
J Clin Oncol; 1987 Aug; 5(8):1240-6. PubMed ID: 3625246
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
10. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma.
Fosså SD; de Garis ST; Heier MS; Flokkmann A; Lien HH; Salveson A; Moe B
Cancer; 1986 Apr; 57(8 Suppl):1700-4. PubMed ID: 3948141
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.
Hutson TE; Molto L; Mekhail T; Elson P; Finke J; Tannenbaum C; Borden E; Dreicer R; Olencki T; Bukowski RM
Clin Cancer Res; 2003 Apr; 9(4):1354-60. PubMed ID: 12684404
[TBL] [Abstract][Full Text] [Related]
15. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.
Wang JC; Walle A; Novogrodsky A; Suthanthiran M; Silver RT; Bander NH; Rubin AL; Stenzel KH
J Clin Oncol; 1989 Dec; 7(12):1885-91. PubMed ID: 2555451
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
Wadler S; Goldman M; Lyver A; Wiernik PH
Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
[TBL] [Abstract][Full Text] [Related]
17. Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell carcinoma: a progress report.
Fosså SD; De Garis ST
Int J Cancer Suppl; 1987; 1():36-40. PubMed ID: 3476476
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy.
Hirsh M; Lipton A; Harvey H; Givant E; Hopper K; Jones G; Zeffren J; Levitt D
J Clin Oncol; 1990 Oct; 8(10):1657-63. PubMed ID: 2213102
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.
Pazdur R; Ajani JA; Patt YZ; Winn R; Jackson D; Shepard B; DuBrow R; Campos L; Quaraishi M; Faintuch J
J Clin Oncol; 1990 Dec; 8(12):2027-31. PubMed ID: 2230894
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
